Altimmune (ALT) Assets Average (2011 - 2026)

Altimmune (ALT) has 16 years of Assets Average data on file, last reported at $307.8 million in Q1 2026.

• On a quarterly basis, Assets Average rose 107.56% year-over-year to $307.8 million in Q1 2026; TTM through Mar 2026 was $307.8 million, a 107.56% increase from a year earlier, with the FY2025 full-year figure at $209.6 million, up 19.8% from the prior year.
• Assets Average for Q1 2026 stood at $307.8 million, up from $249.2 million in the prior quarter.
• Over the last five years, Assets Average for ALT reached as high as $307.8 million in Q1 2026 and fell as low as $143.6 million in Q4 2024.
• Historically, Assets Average has averaged $198.1 million across 5 years, with a median of $197.0 million in 2023.
• Across the five-year window, Assets Average dropped 25.67% in 2025 and jumped 107.56% in 2026, its largest moves.
• Year by year, Assets Average stood at $216.1 million in 2022, then fell by 12.72% to $188.6 million in 2023, then dropped by 23.87% to $143.6 million in 2024, then surged by 73.55% to $249.2 million in 2025, then climbed by 23.51% to $307.8 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $307.8 million in Q1 2026, $249.2 million in Q4 2025, and $204.4 million in Q3 2025.